NCT00941720 · OUTCOME

Overall Survival

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma · Source last updated 2020-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: at 6 months

What was measured

Number of patients alive at the end of the study period

Groups in this outcome

Busulfan Treatment

busulfan: IV busulfan 0.8 mg/kg every 6 hours x 16 doses cyclophosphamide: IV cyclophosphamide 60 mg/kg over 4 hours x 2 days autologous hematopoietic stem cell transplantation: infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Busulfan Treatment	57

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Busulfan Treatment	53	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
53

denoms

counts
group Id
OG000
value
57
units
Participants

description

Number of patients alive at the end of the study period

groups

description
busulfan: IV busulfan 0.8 mg/kg every 6 hours x 16 doses cyclophosphamide: IV cyclophosphamide 60 mg/kg over 4 hours x 2 days autologous hematopoietic stem cell transplantation: infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
id
OG000
title
Busulfan Treatment

param Type

NUMBER

reporting Status

POSTED

time Frame

at 6 months

title

Overall Survival

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice